MEDICUS PHARMA LTD. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities
MEDICUS PHARMA LTD. (MDCX) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities of $2.07 million as of 2023-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities · last filed 2025-03-28
- 2023-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities $2.07M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities |
|---|---|
| 2023-12-31 | $2.07M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |